Allarity Therapeutics, Inc. (ALLR) Stock Forecast
ALLR analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 1 analysts
- Price target
- $11.00 average of analyst targets
- Upside to target
- +1,129.1% from the latest close
- Next earnings
- November 13, 2026 EPS estimate $-0.21
- 52-week range
- $0.81 – $1.77
ALLR analyst ratings
1 analystsNumber of analysts at each rating.
ALLR price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
ALLR earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.21 | −$0.21 | −$0.21 | −$0.19 | −10.5% | 1 |
| Current fiscal year (2026) | −$0.80 | −$0.80 | −$0.80 | −$0.78 | −2.6% | 1 |
| Next fiscal year (2027) | −$0.86 | −$0.86 | −$0.86 | −$0.80 | −7.5% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
ALLR revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 1 |
| Current fiscal year (2026) | $25,000 | $25,000 | $25,000 | −92.2% | 1 |
| Next fiscal year (2027) | $0 | $0 | $0 | −100.0% | 1 |
ALLR EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
ALLR revenue: reported and forecast
ALLR EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.25 | −$0.25 | −$0.25 | −$0.25 | −$0.21 | −16.0% | 1 up · 0 down |
| Current fiscal year (2026) | −$0.92 | −$0.92 | −$0.92 | −$0.92 | −$0.80 | −13.0% | 1 up · 0 down |
| Next fiscal year (2027) | −$0.97 | −$0.97 | −$0.97 | −$0.97 | −$0.86 | −11.3% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
ALLR earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; ALLR beat in 8 of 11.
What analysts expect from ALLR
1 analysts cover Allarity Therapeutics; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $11.00, 1,129.1% above the latest close of $0.90. Analysts expect earnings of −$0.80 per share for 2026, −2.6% from a year earlier. For 2027 the average estimate is −$0.86 per share. Allarity Therapeutics beat the EPS estimate in 8 of the last 11 quarters.
Related: ALLR income statement, ALLR key metrics, ALLR chart. See the ALLR stock overview for the latest quote and news.
ALLR forecast FAQ
What is Allarity Therapeutics's price target?
The average analyst price target for Allarity Therapeutics is $11.00, 1,129.1% above the latest close of $0.90.
Is Allarity Therapeutics a buy, hold or sell?
Of 1 analysts covering Allarity Therapeutics, 1 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Allarity Therapeutics's EPS forecast?
Analysts forecast −$0.80 per share for 2026 (range −$0.80 to −$0.80); for 2027 the estimate is −$0.86.
What is Allarity Therapeutics's revenue forecast?
The average revenue estimate for 2026 is $0.0 million, growth of −92.2%.
When does Allarity Therapeutics report earnings?
Allarity Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 13, 2026; the EPS estimate is $-0.21.
Does Allarity Therapeutics usually beat earnings estimates?
Allarity Therapeutics reported EPS at or above the analyst estimate in 8 of the last 11 quarters.